Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - HC Wainwright upped their Q2 2025 EPS estimates for Entrada Therapeutics in a research note issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.98) for the quarter, up from their previous estimate of ($1.00). HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.65) EPS and Q1 2026 earnings at ($1.13) EPS.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million.

Entrada Therapeutics Trading Down 6.7%

Shares of NASDAQ TRDA opened at $7.69 on Thursday. The firm has a market capitalization of $291.86 million, a price-to-earnings ratio of 4.84 and a beta of 0.04. Entrada Therapeutics has a one year low of $7.10 and a one year high of $21.79. The business has a fifty day simple moving average of $8.76 and a 200 day simple moving average of $13.26.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TRDA. Merck & Co. Inc. bought a new position in shares of Entrada Therapeutics during the 1st quarter worth about $15,728,000. Janus Henderson Group PLC raised its position in Entrada Therapeutics by 21.6% in the fourth quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company's stock worth $36,011,000 after purchasing an additional 368,908 shares in the last quarter. Vanguard Group Inc. raised its position in Entrada Therapeutics by 19.7% in the fourth quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock worth $25,317,000 after purchasing an additional 241,052 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Entrada Therapeutics by 123.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company's stock worth $3,847,000 after purchasing an additional 122,823 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Entrada Therapeutics by 127.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock worth $3,752,000 after purchasing an additional 121,598 shares during the period. Institutional investors own 86.39% of the company's stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.